Murphy Introduces Bipartisan Resolution to Raise Awareness for AADC Deficiency

Washington, D.C. — Today, Congressman Greg Murphy, M.D. issued the following statement after introducing a bipartisan resolution alongside Congressman Stephen Lynch (D-MA) to designate October 23rd, 2024, as AADC Deficiency Awareness Day.

"I am proud to introduce this resolution to bring greater awareness about AADC Deficiency," said Congressman Greg Murphy, M.D. "Increasing recognition of this disease will support patients experiencing symptoms of this disease and guide them toward appropriate care. As a physician of over 30 years, I am honored to amplify awareness of AADC Deficiency in Congress and help inform the public about this rare disease."

"I am proud to continue my work with Rep. Greg Murphy and reintroduce this bipartisan resolution designating October 23, 2024 as 'AADC Deficiency Awareness Day,'" said Congressman Stephen F. Lynch. "Raising awareness of this rare, yet devastating, disease will help patients and families recognize their symptoms and pursue treatment.  I thank the AADC Family Network for their continued advocacy, research, and services they offer those who are affected by this disease, and I am hopeful this resolution will promote medical research and progress to find better treatment for those suffering from AADC Deficiency."

"Building awareness is crucial - not only within the AADC community but also among healthcare providers - enabling them to identify symptoms early and deliver prompt, accurate diagnoses," said Kelly Heger, Director of the AADC Family Network.

Background
AADC Deficiency is a genetic neurologic rare disease that affects approximately 1 in 100,000 people in the United States.

Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency is a genetic neurologic rare disease that severely debilitates a patient's development, motor skills, growth, and cognitive and language skills and limits a patient's life.

AADC Deficiency results from an inherited genetic disease where patients lack the AADC enzyme required to create dopamine and, without dopamine, patients will never achieve motor milestones, such as holding their heads up, sitting, and standing, or develop the ability to communicate or perform basic life functions.

Patients suffering from AADC Deficiency often have unexplained low muscle tone and experience other symptoms like developmental delays and involuntary eye movements.